title: An Exact Procedure for the Evaluation of Reference-Scaled Average Bioequivalence.
abstract: Reference-scaled average bioequivalence (RSABE) has been recommended by Food and Drug Administration (FDA), and in its closely related form by European Medicines Agency (EMA), for the determination of bioequivalence (BE) of highly variable (HV) and narrow therapeutic index (NTI) drug products. FDA suggested that RSABE be evaluated by an approximating procedure. Development of an alternative, numerically exact approach was sought. A new algorithm, called Exact, was derived for the assessment of RSABE. It is based upon the observation that the statistical model of RSABE follows a noncentral t distribution. The parameters of the distribution were derived for crossover and parallel-group study designs. Simulated BE studies of HV and NTI drugs compared the power and consumer risk of the proposed Exact method with those recommended by FDA and EMA. The Exact method had generally slightly higher power than the FDA approach. The consumer risks of the Exact and FDA procedures were generally below the nominal error risk with both methods except for the partial replicate design under certain heteroscedastic conditions. The estimator of RSABE was biased; simulations demonstrated the appropriateness of Hedges' correction. The FDA approach had another, small but meaningful bias. The confidence intervals of RSABE, based on the derived exact, analytical formulas, are uniformly most powerful. Their computation requires in standard cases only a single-line program script. The algorithm assumes that the estimates of the within-subject variances of both formulations are available. With each algorithm, the consumer risk is higher than 5% when the partial replicate design is applied.
authors.affiliation: Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary.
authors.forename: Laszlo
authors.initials: L
authors.lastname: Tothfalusi
authors.affiliation: Department of Pharmacology and Toxicology, University of Toronto, 1 King's College Circle, Toronto, Ontario, M5S 1A8, Canada. l.endrenyi@utoronto.ca.
authors.forename: Laszlo
authors.initials: L
authors.lastname: Endrenyi
mesh_terms: D000465:Algorithms; D016568:Drugs, Generic / Q000592:standards*; D006801:Humans; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards*
chemical_list: D016568:Drugs, Generic
keywords: bioequivalence; exact method; highly variable drugs; narrow therapeutic index; reference-scaled average bioequivalence
references.citation: Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):221-5
references.pmid: 20070293
references.citation: J Pharm Pharm Sci. 2009;12(1):138-49
references.pmid: 19470298
references.citation: Psychol Methods. 2004 Jun;9(2):164-82
references.pmid: 15137887
references.citation: Pharm Res. 2008 Jan;25(1):237-41
references.pmid: 17891552
references.citation: Pharm Res. 2003 Mar;20(3):382-9
references.pmid: 12669957
references.citation: J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80
references.pmid: 3450848
references.citation: Pharm Res. 1999 Feb;16(2):186-90
references.pmid: 10100301
references.citation: Pharm Res. 2015 Jan;32(1):135-43
references.pmid: 25033764
references.citation: Clin Pharmacol Ther. 2015 Mar;97(3):286-91
references.pmid: 25669762
references.citation: Clin Pharmacokinet. 2009;48(11):725-43
references.pmid: 19817502
references.citation: Stat Med. 2000 Oct 30;19(20):2867-78
references.pmid: 11033581
references.citation: Br J Math Stat Psychol. 2006 May;59(Pt 1):97-111
references.pmid: 16709281
references.citation: Pharm Stat. 2012 Jul-Aug;11(4):334-41
references.pmid: 22692852
references.citation: AAPS J. 2015 Jul;17(4):891-901
references.pmid: 25840883
references.citation: Stat Med. 2000 Oct 30;19(20):2885-97
references.pmid: 11033583